This way, while treatment with ghrelin, acylated ghrelin, or synthetic agonists [181,253,256,272] appears advantageous in the long run, the inhibition of BChE [271,273] may provide both long-term and short-term beneficial effects in Alzheimer’s disease. Here, GHRL is linked to early-onset autosomal dominant Alzheimer disease.